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Glyceraldehyde-3-phosfate-dehydrogenaseDendritic cells loaded with antigenic peptides, because of their safety and robust immune stimulation, would be
ideal for induction of immunity to protect against listeriosis. However, there is no currently accepted method to
predict which peptides derived from the Listeria proteome might confer protection. While elution of peptides
from MHC molecules after Listeria infection yields high-afﬁnity immune-dominant epitopes, these individual
epitopes did not reliably confer Listeria protection. Instead we applied bioinformatic predictions of MHC class I
and II epitopes to generate antigenic peptides that were then formulated with Advax™, a novel polysaccharide
particulate adjuvant able to enhance cross-presentation prior to being screened for their ability to induce protec-
tive T-cell responses. A combination of at least four intermediate strengthMHC-I binding epitopes and oneweak
MHC-II binding epitope when expressed in a single peptide sequence and formulated with Advax adjuvant
induced a potent T-cell response and high TNF-α and IL-12 production by dendritic cells resulting in robust lis-
teriosis protection in susceptible mice. This T-cell vaccine approach might be useful for the design of vaccines
to protect against listeriosis or other intracellular infections.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dendritic cells (DCs) present antigenic peptides onMHC I and class II
molecules resulting in stimulation of CD8+ and CD4+T cells, respective-
ly. This ability to activate both CD4 and CD8 T cell responses is the basis
for the effectiveness of DC-based vaccines in prophylaxis against infec-
tions including HIV, Streptococcus pneumonia, Chlamydia trachomatis
or Mycobacterium (Vacas-Cordoba et al., 2013; Cohen et al., 2012;
Rey-Ladino et al., 2014; Kawasaki et al., 2014; Fromen et al., 2015).
Groups at risk of listeriosis include pregnant women, neonates, the
elderly and immune-compromised patients. DC vaccines loaded
ex vivowith peptides and injected back into the host, are highly effective
at inducing cellular immunity and thereby could be useful for Listeria
immunization (Wood and Paterson, 2014).e-3-phosphate dehydrogenase;
mpatibility complex.
eómica y Vacunas, Instituto de
rio 124, Ediﬁcio IDIVAL, Avda,
ain.
guez).
. This is an open access article underThe objective of this studywas toﬁnd a simplemethod to predict the
minimum epitope requirements for a DC vaccine against human listeri-
osis and involved testing DC vaccines in mice susceptible or resistant to
Listeria. C57BL/6 mice have a Listeria resistant allele at the Hc locus on
chromosome 2 and show reduced susceptibility to intravenous, i.v.,
intragastric, i.g. or intraperitoneal, i.p, challengewith Listeriawhen com-
pared to susceptible Balb/c mice (Mainou-Fowler et al., 1988; Poulsen
et al., 2011). Therefore, we used C57BL/6 mice to mimic the population
at low risk of listeriosis, while Balb/c micewere used tomimic high-risk
groups. Two Listeria antigens were selected as the focus of our
study, listeriolysin O (LLO) and the glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) as they have previously been shown to elicit
strong CD4+ and CD8+ T cell responses (Alvarez-Dominguez et al.,
2008; Calderon-Gonzalez et al., 2014, 2015). This was important as
human listeriosis is not well characterised and antigens other than
LLO or GAPDH that induce cellular immunity have yet to be found
(Angelakopoulos et al., 2002; CAD and RCG unpublished results).
Bioinformatic methods that predict T cell epitopes via their ability to
bindMHCmolecules provide a faster and less costly alternative to strat-
egies for selection of T-cell vaccine candidates such asMHC peptide elu-
tion or assays to map T-cell epitopes using complete sets of overlapping
peptides (Geginat et al., 2001; Skoberne and Geginat, 2002). This isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Yu et al., 2002).
Another challenge when developing T-cell vaccines is the restricted
ability of soluble antigens to stimulate strong T-cell responses, which at
least in part reﬂects the lack of MHC class I cross-presentation of such
antigens. Hence to maximise T-cell responses against Listeria an
adjuvant is needed to up-regulate presentation of antigen on MHC
class I and class II molecules on the surface of antigen presenting cells.
Advax™ is a novel polysaccharide adjuvant derived frommicroparticles
of delta β-D-[2-1]poly(fructo-furanosyl)α-D-glucose (delta inulin)
(Cooper and Petrovsky, 2011; Cooper et al., 2013, 2014, 2015). Advan-
tages of Advax include the fact that it has already been shown to be
well tolerated, effective and safe for human use (Gordon et al., 2012,
2014), but most importantly for the current study, its demonstrated
ability to induce potent CD4+ and CD8+ T cell responses against a
wide variety of exogenous antigens including proteins from Japanese
encephalitis, inﬂuenza, hepatitis B, HIV, and SARS coronavirus (Lobgis
et al., 2010; Cristillo et al., 2011; Saade et al., 2013; Honda-Okubo
et al., 2015). Hence, Advax adjuvant had ideal properties for use in our
Listeria T-cell epitope screening programme.
We present a method that combines bioinformatics and structural
predictions of peptide binding to MHC class I and class II molecules
with convenient T-cell readouts. Vaccine predictions were validated




Micewere 8–12week-old female Balb/c from Charles River (France)
or C57BL/6 from our animal facility. DCs were obtained from
femur bone-marrow, differentiated with GM-CSF, and CD11c+ cells
isolated with anti-mouse CD11c-coated magnetic beads and MACS™
separation columns (Miltenyi Biotech Inc., Auburn, CA) (Kono et al.,
2012; Calderon-Gonzalez et al., 2014). DCs used were MHC-
II+CD11c+CD40+CD11b+/−CD86+/−F4/80−Gr-1−.
2.2. Peptides and adjuvants
We used GAPDH1–15, GAPDH1–22, LLO91–99, LLO296–304, LLO189–201,
LLO189–200 and LLO190–201 peptides. Peptides were synthesized at CNB
(CSIC, Madrid) followed by HPLC and mass spectrometry using a
MALDI-TOF Reﬂex™ IV mass spectrometer (Bruker Daltonics, Bremen,
Germany). Peptide purity was N95% after HPLC. Advax™ adjuvant
(Adv1) was supplied by Vaxine (Adelaide, Australia) and was mixed
with antigen by simple admixture immediately before immunization
of mice or in vitro analysis.
2.3. Bacteria
Listeria monocytogenes 10403S strain (LMWT) was obtained from
D.A. Portnoy (University of California, Berkeley, CA, USA).
2.4. Preparation of peptide pulsed DC vaccines
Cultured DCs were ex vivo loaded with 50 μg/ml of GAPDH1–15,
GAPDH1–22, LLO91–99, LLO296–304, LLO189–200, LLO190–201 or LLO189–201
peptides for 24 h in the presence of 50 μg/ml of Advax. Supernatants
were collected and stored at−80 °C for cytokine measurements. Cells
were analysed for cell surface markers by FACS.
2.5. Measurement of viability and apoptosis
Cultured DCs were also analysed for viability incubating cells with
Trypan-blue. Cells stained with Trypan-blue were considered deadcells,while cells non-stainedwith the dyewere viable. Cellswere count-
ed in a Neubauer haemocytometer and results were expressed as the
mean of the percentages of viable cells ± SD. DCs were also examined
for apoptosis by FACS analysis after double staining with 7-AAD and
annexin-V (BD-Biosciences). In brief, DCs were incubated with 7-AAD
and annexin-V-APC for 60min at 4 °C, washed and analysed by ﬂow cy-
tometry. Double negative cells correspond to cells non-permeable to
any reagent and therefore alive (Q3 region). Cells positive for
annexin-V but negative for 7-AAD corresponded to early apoptotic
cells (Q4 region). Double positive cells for annexin-V and 7-AAD
corresponded to late apoptotic cells (Q2 region) and cells negative for
annexin-V but positive for 7-AAD correspond to necrotic cells (Q1
region). Results are expressed as the mean of the percentages of late
apoptotic cells (L-apoptosis) or early apoptotic cells (E-apoptosis)± SD.
2.6. T-cell responses elicited by DC-LLO or DC-GAPDH vaccines
For delayed type hypersensitivity (DTH) analysis, Balb/c and C57BL/
6 mice immunised i.pwith LMWT (5 × 103 CFU) were inoculated 7 days
later in left hind footpads with DC vaccines (106 cells/mice) in the
presence or absence of Advax (50 μg/ml). Non-inoculated right hind
footpads served as negative controls. Positive controls of this assay
included DC pre-infected in vitro with wild type LM (DC-LMWT) as
previously reported (Calderon-Gonzalez et al., 2015). After 24 h, we
measured the footpad thickness with a calliper. T cell results in the
footpads are expressed in millimetres as the mean of three different
experiments ± SD.
2.7. Vaccination protocols
Vaccines used were DC-LLO91–99, DC-LLO296–304, DC-LLO189–201, DC-
LLO189–200, DC-LLO190–201, DC-GAPDH1–15 and DC-GAPDH1–22 (1 × 106
cells/mice). Mice were immunised into the peritoneal cavity (i.p)
(n = 5) in the presence or absence of Advax (50 μg/ml) or left non-
vaccinated (NV). Seven days after immunization, Balb/c and C57BL/6
mice were challenged i.p with 103 and 104 CFU of LMWT/mice, respec-
tively, and then bled before termination (Lauer et al., 2008). Sera were
stored at−80 °C to measure cytokines by FACS analysis using the CBA
kit thatmeasures all Th1 cytokines of a sample at the same time (Becton
Dickinson, Palo Alto, CA, USA). Data were analysed using the FlowJo
software (Treestar, Ashland, OR). Samples were performed in triplicate
and the results are themean±SDof two separate experiments. ANNOVA
was used for statistics with the cytokine measurements. At termination
spleens and livers were homogenized and CFUs counted in blood agar
plates. To measure CD4+ frequencies producing intracellular IFN-γ,
spleen cells were cultured in 96-well plates (5 × 106 cells/ml) and stim-
ulated with GAPDH1–15 or GAPDH1–22 peptides (5 μg/ml each peptide)
for 5 h in the presence of brefeldin A as previously reported (Calderon-
Gonzalez et al., 2014). Next, cells were surface labelled for CD4, ﬁxed
and permeabilized with cytoﬁx/cytoperm kit before staining for intracel-
lular IFN-γ (BD Biosciences). FACS data were analysed using FlowJo
software (Treestar, Ashland, OR). After sample acquisition, data were
gated for CD4+ events, and the percentages of cells expressing IFN-γ
determined according to the manufacturer's recommendations. Results
were corrected according to the percentages of total CD4+ cells. Samples
were tested in triplicate and the results are the mean ± SD of two
separate experiments.
2.8. Frequencies of CD8+-LLO or GAPDH speciﬁc T cells
To conﬁrm the frequency of LLO91–99, LLO296–304, GAPDH1–15 or
GAPDH1–22 speciﬁc CD8 T cells producing IFN-γ, we used recombinant
soluble dimeric mouse H-2Kb:Ig (for C57BL/6 mice) or H-2Ld:Ig (for
Balb/c mice) fusion proteins following the manufacturer's instructions
(DimerX I; BD Bioscience) and as previously described (Lauer et al.,
2008; Calderon-Gonzalez et al., 2014).
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LLO91–99 or GAPDH1–22 peptides were prepared at 50 μg/ml in coat-
ing buffer (50 nM of Na2CO3 at pH 9.7) and used to coat NuncMaxiSorp
plates overnight at 4 °C. Next, plates were blockedwith 1% BSA in PBS at
RT for 30min andmice sera diluted 1/200 in PBS-0.5% BSA and incubat-
ed for 1 h at RT.Mice IgMwas detectedwith a goat anti-mouse IgM con-
jugated with horseradish peroxidase (0.8 μg/ml) and enzymatic
reactions developed with tetramethylbenzidine in citric/acetate buffer
and H2O2. Reactions were stopped with 50 μl of H2SO4 (0.8 M) and
absorbances measured at 450 nm in the ELISA reader. Results were
expressed as absorbance units of triplicates ± SD.
2.10. Statistical analysis
For statistical analysis, Student's t test was applied. ANOVA analysis
was applied to cytokine measurements. P ≤ 0.05 was considered signif-
icant. GraphPad software was used for generation of graphs.
2.11. Ethics statement
This studywas carried out in accordancewith the Guide for the Care
and Use of Laboratory Animals of the Spanish Ministry of Science,
Research and Innovation. The Committee on the Ethics of Animal
Experiments of the University of Cantabria approved the protocol
(Permit Number: 2012/06) that follows the Spanish legislation
(RD 1201/2005). All surgerieswere performed under sodium pentobar-
bital anaesthesia, and all efforts were made to minimize suffering.
3. Results and discussion
3.1. Bioinformatics approach to classify Listeria epitopes
The objective of this study was to design a simple experimental ap-
proach that predicted the minimal epitope requirements to load and
prepare DC vaccine formulations able to protect against listeriosis. We
focussed on the Listeria antigens LLO and GAPDH as vaccine candidates
since sera from patients recovering from listeriosis recognized various
peptides from these antigens (Angelakopoulos et al., 2002; CAD and
RCG unpublished results). Listeriosis is characterised by low humoral
but robust T cell responses (Pamer, 2004). Previously T-cell epitopes
for Listeria vaccine design have been identiﬁed by peptide elution
from MHC molecules of Listeria-loaded macrophages (Geginat et al.,
2001; Skoberne and Geginat, 2002). Since this approach is technically
challenging, predominantly only identiﬁes high afﬁnity epitopes and is
performed using macrophages which are less efﬁcient at antigen pre-
sentation cells than DC, it may fail to identify many other relevant and
protective Listeria T-cell epitopes. There is also no consensus of whether
high, medium or low afﬁnity epitopes may represent the best vaccine
candidates. Bioinformatics approaches have been used in other infec-
tious diseases to identify T-cell epitopes to include in vaccines with
great success (Yu et al., 2002; Stephenson et al., 2015). Hence we used
a bioinformatics approach to screen for potential T cell epitopes in
LLO and GAPDH and followed this with a modiﬁed delayed-type-
hypersensitivity (DTH) test to identify T-cell epitopes with potential
to provide protection against human and veterinary listeriosis. As posi-
tive controls we used ﬁve known LLO epitopes previously identiﬁed by
the elution method (Geginat et al., 2001). For T-cell epitope prediction
we used IEDB, a bioinformatic prediction resource Consensus tool that
combines predictions from artiﬁcial neural network (ANN), SMM and
Comblib for GAPDH binding predictions (Nielsen et al., 2003; Peters
and Sette, 2005; Sidney et al., 2008; Kim et al., 2012). IEDB analysis
predicted that good MHC class I binders showed percentile ranks b10
and weak binders percentile ranks b100. Similarly, good MHC class II
binders showed percentile thresholds b50, intermediate binders b500
and low binders b5000.GAPDH1–15 contained four epitopes predicted to be good binders for
H-2Kb, H-2Kd and H-2Ld MHC-I molecules, and one predicted interme-
diate binding epitope for IAb and low binder to IAd (lower right image
in Fig. 1A). GAPDH1–22 contained six epitopes predicted to be good
binders to H-2Kd and H-2Ld, six epitopes predicted to be intermediate
binders to IAb and one epitope predicted to be a low binder to IAd
(GAPDH binding values in Fig. 1A). These data indicated that
GAPDH1–15 and GAPDH1–22 epitopes were able to bind to different
MHC-I and MHC-II molecules of Balb/c and C57BL/6 mice strains.
Analysis of LLO for epitopes indicated that LLO91–99 was predicted to
be a strong binder toH-2Kd (0.7 values) and also aweakbinder toH-2Kb
MHC-I (67 values); LLO296–304 peptide was predicted to be a strong
binder to H-2Kb (score 0.2), a weak binder to H-2Kd (score 32) and an
intermediate binder to H-2Ld (score 12.5) and LLO189–201 was predicted
to be a strong binder to IAb (score 51.3) and low binder to IAd (score
5326). LLO189–200 and LLO190–201 peptides were not predicted to bind
to IAd (score N 10000) and to be weak binders to IAb (scores 85 and
75, respectively) (Calderon-Gonzalez et al., 2015). All LLO epitope pre-
dictionswere in agreementwith the previouslyMHC-I andMHC-II elut-
ed LLO epitopes (Geginat et al., 2001; Skoberne and Geginat, 2002).
However, the bioinformatic analysis also predicted new MHC binding
abilities for these LLO epitopes. Hence, the LLO91–99 epitope previously
eluted from H-2Kd was predicted to be a weak binder to H-2Kb,
LLO296–304 epitope eluted fromH-2Kbwas predicted to be aweak binder
to H-2Kd, LLO189–201 and LLO190–201 epitopes eluted from IAb were pre-
dicted to beweak binders to IAd, and LLO189–200 epitope eluted from IAd
was predicted to be a weak binder to IAb. Therefore, the bioinformatics
analysis identiﬁed a higher number of potential binding epitopes than
the elutionmethods.We next studiedwhere the predicted LLO epitopes
were situatedwithin the recently reported LLO crystal structure (Köster
et al., 2014) PBDI: 4CDB (left image, Fig. 1A). LLO showed 4 domains
(D1, D2, D3 and D4) that contained several β-sheets and α-helices
with D4 being the binding domain to the phagosomal membranes.
Since no crystal structure from Listeria GAPDH was available, we used
the Automated Comparative Protein Modelling Server SWISS-MODEL
available at: (http://www.expasy-ch/swissmod/SWISS-MODEL.html)
to produce a theoretical 3D model (right image, Fig. 1A). LLO epitopes
that bind to MHC-I were tight or wide loops (pink and green LLO se-
quences, respectively, Fig. 1A), while epitopes that bind to MHC-II
contained α-helices (purple LLO sequence, Fig. 1A). A similar pattern
was observed for GAPDH, with GAPDH1–22 and GAPDH1–15 epitopes
that bind to MHC-I containing tight loops and epitopes that bind to
MHC-II molecules containing two α-helices. According to this rule, we
predicted that GAPDH1–22 and GAPDH1–15 epitopes containing tight
loops and two α-helices that are able to simultaneous bind to H-2Kb,
H-2Kd, H-2Ld, IAb and IAd might be the best candidates for a T-cell
based listeriosis vaccine. Next, the LLO91–99 epitope containing tight
loops and LLO296–304 epitope with wide loops that both bind to MHC-I
molecules and the LLO189–201 epitope containing two complete α-
helices that bind to MHC-II molecules, were identiﬁed as good vaccine
candidates as they were able to bind to MHC from both mice strains.
LLO189–200 and LLO190–201 epitopes that contained one α-helix and
bind to MHC-II molecules of one mice strain exclusively were classiﬁed
using this algorithm as poor vaccine candidates.
3.2. Evaluation of the quality of DC vaccine formulations
Having identiﬁed candidate vaccine epitopes we next wished to
exclude any negative effects of the relevant peptides on the viability of
the proposed DC vaccine vectors. DC vectors need to remain viable to
fully activate T cells in the draining lymph nodes, a process that takes at
least 24 h. Therefore, we examined the effect of the relevant LLO and
GAPDH peptides on DC cytotoxicity and activation after 24 h of culture,
the time required for DC loading with peptides (Pion et al., 2010; Kono
et al., 2012; Vacas-Cordoba et al., 2013; Calderon-Gonzalez et al., 2014).
Cytotoxicity was examined with Trypan-blue staining and apoptosis
ig. 1.Methodology to predict efﬁcient vaccine epitopes for DC vaccine formulations. (A) diagram showing the bioinformatic strategy for epitope prediction including the 3D-structure of LLO
ased on the recently reported crystal structure (Köster et al., 2014) and the relevant MHC-I and MHC-II epitopes in Balb/c and C57BL/6 mice. The purple sequence corresponds to LLO189–201
eptide that contains LLO189–200 and LLO190–201 MHC-II epitopes and the pink sequence corresponds to LLO91–99 MHC-I epitope. The green sequence corresponds to the LLO296–394 MHC-I epi-
pe. On the right, the predicted 3D structure of GAPDH is shown with the GAPDH1–22 peptide highlighted in red. The lower image shows an enlargement of amino acids 3–15 of GAPDH1–15
pitope. The sequences included on the right correspond toMHC binding predictions performedwith IEDB Consensus tool. (B) DCswere incubatedwith 50 μg/ml of peptides for 24 h and then
ained with Trypan blue to assay cytotoxicity (grey bars) or incubated with 7-ADD and annexin-V to analyse apoptosis by FACS (black and white bars). An example of apoptosis read-out is
own in left panel. Cytotoxicity results are expressed as the number of cells±SD and experimentswere performed in triplicate. Apoptosis results are expressed as themean of the percentages
f early apoptotic (Q4 region), late apoptotic (Q2 region) or necrotic cells (Q1 region)± SD (P b 0.05). (C) DC fromBalb/c or C57BL/6micewere differentiated in vitrowith 30 ng/ml of GM-CSF
r 5 days, detached and positively selected using anti-mouse CD11c-coatedmagnetic beads andMACS separation columns. CD11c+DCwere loaded ex vivowith different peptides in the pres-
nce of 50 μg/ml of Advax: LLO91–99, LLO189–200, LLO190–201, LLO189–201, LLO296–304, GAPDH1–15 or GAPDH1–22 peptides (50 μg/ml) for 24 h or left unloaded (DC-CONT). Cells were washed and
nalysed using a FACSCanto ﬂow cytometer. The percentages of CD11c+MHC-IIhighCD40+CD86+ positive cells are shown. Results are expressed as the mean ± SD of triplicate samples
b 0.05). (D) C57BL/6 (black bars) or Balb/c mice (white bars) were immunised i.pwith 5 × 103 CFU of Listeria/mouse for 7 days and then left hind footpads were inoculated with 1 × 106
lls of differentDC-LLO andDC-GAPDHvaccines or saline (NT) for 24h in thepresence of Advax (250 μg),while right hind footpadswerenot inoculated and served as controls. Footpad swelling
as measured with a calliper and expressed as the differences in mm between left and right hind footpads. Results are expressed as the mean ± SD of three different experiments (P b 0.05).
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ferent concentrations of LLO91–99, LLO189–201, LLO189–200, LLO190–201,
LLO296–304, GAPDH1–15 or GAPDH1–22 peptides (0–500 μg/ml). None of
the LLO or GAPDHpeptides at doses of 50 μg/ml and below caused DC cy-
totoxicity, early (E-apo of Q4 region or E-apoptosis in black bars of Fig. 1B)
or late apoptosis (L-apop of Q2 region or L-apoptosis in white bars of
Fig. 1B). As the highest concentrations of peptides (500 μg/ml)were asso-
ciated with slightly lower DC viability (Table 1), we selected 50 μg/ml as
the on-going loading concentration for our DC vaccines.
An important issue for DC vaccines is their activation state, as this
improves the quality of the resulting T-cell responses. Activated DCs
show a characteristic CD11c+MHC-II+CD40+CD86+ phenotype that
corresponds with higher vaccine efﬁciency (Pion et al., 2010; Kono
et al., 2012; Vacas-Cordoba et al., 2013). Peptides by themselves gen-
erally do not activate DC, although longer peptides may sometimes
do so (Calderon-Gonzalez et al., 2014). Since LLO and GAPDH pep-
tides differ signiﬁcantly in their length, we standardised the experi-
ment by mixing the peptides with 50 μg/ml of Advax adjuvant prior
to DC loading for 24 h. Advax was included, as it has been previously
shown to modulate DC activity and potently enhance CD4+ and
CD8+ T cell responses to Listeria antigens (Rodriguez-Del Rio et al.,
2015). We also included LPS (10 ng/ml) as a classical DC activator
(DC-LPS) (Kono et al., 2012; Calderon-Gonzalez et al., 2014) as well
as untreated control DC (DC-CONT). LPS induced the highest
frequency of CD11c+MHC-IIhighCD40+CD86+ DC (CD11c+ DC)Table 1
Lack of cytoxicity induction of LLO and GAPDH peptides.
Reagent DC viabilitya
LLO91–99 (μg/ml)
500 1.69 ± 0.132 × 106
50 1.79 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
LLO189–201 (μg/ml)
500 1.69 ± 0.132 × 106
50 1.77 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
LLO190–201 (μg/ml)
500 1.69 ± 0.132 × 106
50 1.76 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
LLO190–201 (μg/ml)
500 1.67 ± 0.132 × 106
50 1.78 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
LLO296–304 (μg/ml)
500 1.61 ± 0.132 × 106
50 1.77 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
GAPDH1–15 (μg/ml)
500 1.73 ± 0.132 × 106
50 1.78 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
GAPDH1–22 (μg/ml)
500 1.69 ± 0.132 × 106
50 1.78 ± 0.120 × 106
5 1.78 ± 0.113 × 106
0.5 1.79 ± 0.128 × 106
a In vitro cytoxicity assayed using DC incubated with different doses
of peptides (0–500 μg/ml) for 24 h and then stained with Trypan blue.
Results are expressed as the number of viable cells ± SD and experi-
ments were performed in triplicates (P b 0.05).followed by GAPDH1–22 and GAPDH1–15 peptides. LLO91–99 induced
intermediate numbers of CD11c+ DC. LLO296–304 and LLO189–201
peptides also induced signiﬁcant numbers of CD11c+ DC while
LLO189–200 and LLO190–201 induced no CD11c+ DC at all (Fig. 1C).
We applied these results to the bioinformatics predictions to identify
whether there were any epitope characteristics, which predicted the
highest DC activation in both mice strains. Notably, the GAPDH1–15 epi-
tope that induced a high DC activation (Fig. 1C) had fourMHC-I binding
sequences in tight loops and one MHC-II binding sequence containing
two α-helices (Fig. 1A). Intermediate DC activation occurred with the
LLO91–99 epitope (DC-LLO91–99 bars in Fig. 1C) that corresponded with
a tight loop (pink LLO loop in Fig. 1A) that binds to MHC-I molecules
in both mice strains. Lower DC activation was observed with
LLO296–304 epitopes (DC-LLO296–304 bars in Fig. 1C), which corresponded
with a wide loop that binds to MHC-I molecules in both mice strains
(green LLO epitopes in Fig. 1A). Very low DC activation was observed
only with LLO189–201 epitope (DC-LLO189–201 bars in Fig. 1C) that
corresponded with two complete α-helices that bind to MHC-II
molecules in both mice strains (purple LLO epitopes in Fig. 1A). No DC
activation was observed with LLO189–200 or LLO190–201 epitopes
(Fig. 1C) that corresponded with one α-helix that binds exclusively to
MHC-II of only one mice strain. This analysis suggests that epitopes
that bind MHC-I are more likely to induce DC activation than MHC-II
binders.
3.3. Quantiﬁcation of T-cell responses elicited by DC-vaccine formulations
Next we sought to develop an assay to predict the DC epitopes
that elicited the highest T cell responses, in vivo. For this purpose,
we adapted a classical delayed-type-hypersensitivity (DTH) test
(Mohamed et al., 2012), where DC vaccines loaded with LLO or
GAPDH peptides plus Advax adjuvant (50 μg/ml) were inoculated into
the foot pads of previously Listeria-challenged mice and the DTH
response measured as the degree of footpad swelling 24 h post-
inoculation (Fig. 1D). We included a positive control of DTH response,
DC infected in vitro with wild type LM (DC-LMWT) that induced a high
degree of footpad swelling as previously reported (Calderon-Gonzalez
et al., 2015). In both mice strains, DC-GAPDH1–15 and DC-GAPDH1–22
vaccines generated the highest DTH responses, similar to the positive
control DC-LMWT, followed by DC-LLO91–99, then DC-LLO296–304 and
lastly DC-LLO189–201. DC-LLO190–201 induced a low DTH response only
in susceptible Balb/cmice and DC-LLO189–200 induced no response in ei-
ther strain (Fig. 1D). These results indicated that the size of the DTH re-
sponses elicited by the DC epitope vaccines formulated with Advax
adjuvant, correlated well with the ability of the peptides to induce DC
activation and with the initial bioinformatic predictions (Fig. 1B–C).
The removal of Advax adjuvant from the DC vaccine formulations re-
duced all DTH results ~5-fold but the Advax adjuvant did not modify
the controls (data not shown), conﬁrming that its action was via en-
hancement of antigen-speciﬁc T-cell responses. This is consistent with
enhancement of antigen-speciﬁc T-cell responses observed with
Advax adjuvant in other contexts such as when combined with inﬂuen-
za, hepatitis B or SARS coronavirus vaccines (Honda-Okubo et al., 2012,
2015; Saade et al., 2013).
Next, we tested whether the strong DTH results for speciﬁc DC vac-
cines correlated with a Th1 cytokine response, as reﬂected in the super-
natants of DC loaded with the different LLO and GAPDH peptides in the
presence of Advax adjuvant as in Fig. 1A. We observed that for both
mouse strains, DC-GAPDH1–22, DC-GAPDH1–15 and DC-LLO91–99
vaccines induced the highest TNF-α levels followed by DC-LLO296–304.
DC-LLO189–201, DC-LLO190–201 and DC-LLO189–200 vaccines induced no
TNF-α (Table 2). Only DC-GAPDH1–22 and DC-GAPDH1–15 induced sig-
niﬁcant levels of IL-12 in both mice strains, with IL-12 having been
shown to correlate with protective vaccine responses against listeriosis
(Kono et al., 2012 and Calderon-Gonzalez et al., 2014). DC-LLO91–99
vaccines produced lowbut signiﬁcant levels of IL-12 in bothmice strains
Table 2
Th1 cytokines production by DC vaccines loaded with peptides in the presence of Advax.
Epitopea Th1-cytokines (pg/ml)b
Cytokines Balb/c C57BL/6
LLO91–99 TNF-α 1495 ± 102 1475 ± 118
IL-12 4.5 ± 0.1* 0.45 ± 0.05
LLO296–304 TNF-α 315 ± 0.9 310 ± 0.9
IL-12 0 ± 0 0 ± 0
LLO190–201 TNF-α 15 ± 0.7 10 ± 0.8
IL-12 0.11 ± 0 0.12 ± 0.04
LLO189–200 TNF-α 10 ± 0.8 11 ± 0.7
IL-12 0 ± 0 0 ± 0
LLO189–201 TNF-α 25 ± 0.9 20 ± 0.9
IL-12 0 ± 0 0 ± 0
GAPDH1–22 TNF-α 1635 ± 100 1721 ± 113
IL-12 25 ± 0.8* 24 ± 0.8*
GAPDH1–15 TNF-α 1515 ± 120 1510 ± 138
IL-12 24 ± 0.8* 22 ± 0.9*
Asterisks show the IL-12 signiﬁcant levels.
a Levels of pro-inﬂammatory TNF-α and IL-12 cytokines were analysed in sera of dif-
ferent DC vaccinated Balb/c or C57BL/6mice in the presence of Advax adjuvant (50 μg/ml)
by CBA. Results are expressed as cytokine concentration (pg/ml of mean ± SD, P b 0.05).
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LLO189–200 induced no detectable IL-12 levels (Table 2). Thus, only the
DC epitopes originally predicted by bioinformatic analysis to be the
best CD8 T-cell epitopes and which produced the highest DTH re-
sponses in vivowere associatedwith signiﬁcant IL-12 production by DC.3.4. Validation of proposed methods of epitope prediction for listeriosis
vaccines
Next, to verify the above predictions, susceptible Balb/c and resistant
C57BL/6 mice were immunized with DC-LLO91–99, DC-LLO296–304, DC-
LLO189–200, DC-LLO190–201, DC-LLO189–201, DC-GAPDH1–15, or DC-
GAPDH1–22 together with Advax (50 μg/ml) or were left non-
vaccinated (NV). Micewere immunized i.pwith a single dose of vaccine
and 7 days later were administered a Listeria challenge (see Methods
section for procedures). Five days post-challenge, all mice were bled,
sacriﬁced and spleens recovered to count Listeria CFU and analyse im-
mune cell populations (Fig. 2A and Table 3). DC-GAPDH1–15 and DC-
GAPDH1–22 provided the greatest protection in both Balb/c and C57BL/
6mice (~97 and 99%, respectively) (Fig. 2A). DC-LLO91–99 also conferred
signiﬁcant protection in both Balb/c and C57BL/6 mice (90 and 93%,
respectively). DC-LLO296–304 vaccine conferred strong protection in
C57BL/6 mice (~90%) (Fig. 2A) but only intermediate levels of protec-
tion in Balb/c mice (~60%) (white bars in Fig. 2A). DC-LLO189–200, DC-
LLO190–201, and DC-LLO189–201 vaccines conferred no signiﬁcant protec-
tion in either strain (2 and 5%, respectively). Vaccination efﬁciency was
associated with normal spleen size (images of DC-GAPDH1–15 vaccine
recipients shown in Fig. 2A) compared with enlarged spleens (images
of NV mice in Fig. 2A) and granulomatous livers of non-vaccinated
mice (data not shown). We also evaluated several immunological pa-
rameters induced by the most protective DC vaccines. DC-GAPDH1–15
and DC-GAPDH1–22 vaccines were found to induce the highest frequen-
cies of IFN-γ-producing CD8+ T cells in both C57BL/6 and Balb/c mice
(4.0–4.2%, respectively) followed by DC-LLO91–99 vaccine with 3.0%
frequency as assessed by FACS using H2-Kb:Ig-peptide dimers or 2.16%
frequency using H2-Ld:Ig-peptide dimers (right plot in Fig. 2B). DC-
LLO296–304 vaccine induced very low 0.87% CD8+ T cell frequencies in
C57BL/6 mice and undetectable frequencies in Balb/c mice (DC-
LLO296–304 bars in Fig. 2B). Only DC-GAPDH1–15 and DC-GAPDH1–22 vac-
cines induced detectable numbers of IFN-γ producing peptide-speciﬁc
CD4+ T cells (1.05 and 1.76%, respectively) (Fig. 2B show C57BL/6
data, values in Balb/c were 1.05 and 1.76%). In summary, our results
with DC-GAPDH vaccines conﬁrmed that CD8+ T cell responses weremore relevant than CD4+ T cell responses for Listeria protection.
GAPDH1–15 and GAPDH1–22 peptides presented high numbers of MHC-
I binding epitopes in listeriosis resistant and sensible mice, explaining
DC-GAPDH vaccines induced similar CD8+ T cell responses and Th1-
cytokines in both mice strains.
Antibody production and B cell responses seemed to play no role in
listeriosis (Pamer, 2004). However, antibodies against LLO seemed to
participate in neutralization of Listeria growth (Edelson and Unanue,
2001). Here, we conﬁrmed no variation in B cell numbers among non-
vaccinated (NV), vaccinatedmice (DC vaccines) or non-infected control
mice (control) with similar percentages of CD19+ positive cells (Spleen
markers rows in Table 3). Nevertheless, DC-GAPDH1–22 (DC-GAPDH1–22
rows in Table 3) or DC-GAPDH1–15 vaccines (data not shown) produced
high levels of anti-GAPDH1–22 IgM antibodies compared to non-
vaccinated mice (NV) that correlated with an increase in the percent-
ages of CD4+ T cells. DC-LLO91–99 vaccinated mice produced no signiﬁ-
cant levels of anti-LLO91–99 IgM antibodies compared to NV and
presented low percentages of CD4+ T cells (DC-LLO91–99 rows in
Table 3). These data strongly suggested that vaccines conferring the
highest protection in listeriosis induced prominent antigen-speciﬁc T
cell responses and promoted also antigen-speciﬁc B cell responses, sug-
gesting a collaborative role of B and T cell responses in listeriosis protec-
tion (Edelson and Unanue, 2001; Alvarez-Dominguez et al., 2008;
Calderon-Gonzalez et al., 2014, 2015).
Finally, vaccination with DC-GAPDH1–15, DC-GAPDH1–22 or DC-
LLO91–99 vaccine induced high levels of MCP-1, TNF-α and IFN-γ in
bothmice strainswhereasDC-LLO296–304 vaccine induced only interme-
diate levels of TNF-α in C57BL/6 mice (DC-LLO296–304 bars in Fig. 2C).
Only DC-GAPDH1–15 and DC-GAPDH1–22 vaccines induced high IL-12
levels, post-challenge, in both mice strains (right plot in Fig. 2C). DC-
LLO91–99 vaccine induced low but signiﬁcant levels of IL12 in both
mice strains (Kono et al., 2012; Calderon-Gonzalez et al., 2014). Thus
the Listeria T-cell epitopeprediction algorithmdescribed in themethods
was validated in vivo and shown to predict vaccine effectiveness after
Listeria vaccination of low and high susceptibility mice. Advax adjuvant
was conﬁrmed to be important to induction of a potent Listeria antigen
speciﬁc T-cell response, consistent with its ability to enhance vaccine
protection in other models including inﬂuenza, where it similarly en-
hanced CD4+ and CD8+ T-cell responses and Th1 cytokine production
(Honda-Okubo et al., 2012). The present results conﬁrm that Advax ad-
juvant has the ability to induce MHC I cross-presentation of Listeria an-
tigens thereby resulting in activation of Listeria-speciﬁc CD8 T cells,
although the mechanism by which it might induce cross-presentation
is currently unknown. One possibility currently under investigation is
that Advax induces cross-presentation via activation of CD4+ T helper
cells that signal to upregulate cross-presentation pathways in antigen
presenting cells. When considering design of Listeria vaccines, a major
advantage of Advax over other potential T-cell adjuvants is its lack of
toxicity as evidenced by data from preclinical studies (Lobgis et al.,
2010; Cristillo et al., 2011; Eckersley et al., 2011; Layton et al., 2011;
Larena et al., 2013; Petrovsky et al., 2013; Saade et al., 2013;
Bielefeldt-Ohmann et al., 2014; Feinen et al., 2014; Honda-Okubo
et al., 2014, 2015) as well as human clinical trials (Gordon et al., 2012,
2014).
4. Conclusions
Newmethods of T-cell epitope screeningwould greatly assist design
of DC vaccine formulations, including for protection against listeriosis.
Here we have developed amethod for DC vaccine design that combines
bioinformatic prediction of MHC binding epitopes with 3D structural
predictions and DC functional assays utilising Advax, a potent T-cell ad-
juvant, to amplify the signal. Using thesemethodologies, we successful-
ly predicted Listeria epitopes thatwhen incorporated in DC vaccines and
administered to either Balb/c or C57BL/6 mice were able to confer pro-
tection against Listeria challenge. Peptides binding at least four MHC-I
Fig. 2.Experimental validation of epitopepredictionswith vaccination assays. DC vaccineswere tested for their immunogenicity and ability to protect against listeriosis. (A) C57BL/6 (black bars
or Balb/c (white bars) mice were vaccinated i.pwith different DC vaccine vectors (1 × 106 cells). DC-CONT, DC-GAPDH1–15, DC-GAPDH1–22, DC-LLO91–99, DC-LLO296–304, DC-LLO189–200, DC
LLO189–201 or DC-LLO190–201 in the presence of Advax (50 μg/ml) or left not vaccinated (NV) (n = 5 mice/group) and 7 days later were challenged i.pwith 103 CFU LM (for Balb/c mice) o
104 CFU LM (for C57BL/6 mice). Results of spleen homogenates are expressed as CFU (mean± SD) and obtained from triplicate samples of three independent experiments (P b 0.01). Image
correspond to spleens of non-vaccinated mice (NV) showing splenomegaly versus DC-GAPDH1–15 vaccinated C57BL/6 mice. (B) C57BL/6 or Balb/c mice were vaccinated and then challenged
with LM as in A and examined for speciﬁc GAPDH T-cell responses by intracellular cytokine staining (lower plots). Homogenates were stimulated 5 h with GAPDH1–15 or GAPDH1–22 peptide
then intracellular cytokine staining performed. Histograms show the frequency of GAPDH1–15 (left lower plot) and GAPDH1–22-speciﬁc CD4+ T cells (right lower plot) and IFN-γ producers in
C57BL/6 spleen homogenates. Experiments were performed in triplicate and results are expressed as mean± SD (P b 0.05). To measure the frequencies of CD8+ GAPDH-speciﬁc immune re
sponses (right plots), splenocytes fromvaccinatedmicewere incubatedwith recombinant dimericH-2Kb:Ig (black bars) orH-2Ld:Ig (white bars) fusionproteins loadedwith LLO91–99, LLO296–304
GAPDH1–15 or GAPDH1–22 peptides, respectively. The staining cocktail contained the dimeric fusion protein loaded with the peptides, CD8 and IFN-γ antibodies. CD8+ cells were gated for anti
IFN-γ staining (%Gated dimer-CD8) to calculate the frequencies of CD8+-GAPDH1–15 or CD8+-GAPDH1–22 restricted cells and IFN-γ producers. Resultswere expressed as themean± SD of trip
licates (P b 0.05). (C) Levels of pro-inﬂammatory cytokinesMCP-1, TNF-α or IFN-γwere analysed inmouse sera from DC-vaccinated and LM challengedmice as in A using the CBA kit (BD Bio
sciences) by ﬂow cytometry (see Material and Methods). Upper plot correspond to cytokine measurements of C57BL/6 mice and lower plot to Balb/c mice. Results expressed as cytokine
concentration (pg/ml) of mean ± SD, P b 0.05. (D), IL-12 levels of sera from A measured with the CBA kit and expressed as cytokine concentration (pg/ml) of mean ± SD, P b 0.05.











B cell responses elicited by DC-vaccines in the presence of Advax.
Vaccinea Anti-peptide IgM antibodiesb
LLO91–99 GAPDH1–22
Control 0.156 ± 0.05 0.163 ± 0.04
NV 0.517 ± 0.02 1.021 ± 0.02
DC-GAPDH1–22 0.712 ± 0.02 2.011 ± 0.05
DC-LLO91–99 0.583 ± 0.03 1.276 ± 0.02
Vaccinea Spleen markersc
CD19+ CD4+ CD8+ CD11c+-CD86+
Control 19 ± 0.5 7 ± 0.3 8 ± 0.2 0.5 ± 0.02
NV 15 ± 0.5 18 ± 0.6 17 ± 0.5 26 ± 0.8
DC-GAPDH1–22 15 ± 0.3 26 ± 0.4 28 ± 0.5 70 ± 0.7
DC-LLO91–99 15 ± 0.2 7 ± 0.2 27 ± 0.3 70 ± 0.6
a C57BL/6 (Table) or Balb/c (data not shown) mice were vaccinated in the presence of
Advax (50 μg/ml) with DC-GAPDH1–22 or DC-LLO91–99 vaccines or non-vaccinated (NV). 7
days post-vaccination, vaccinated and NV mice were infected with 5 × 103 CFU of LMWT
for 5 days. Controlmicewere non-vaccinated andnon-infected. Next, micewere sacriﬁced
and sera collected and stored at−80 °C. Spleens were homogenized for further analysis.
b Sera from vaccinated, non-vaccinated or control mice were thawed and examined
peptide-ELISA as described inMethods section. Reactions were developed with goat anti-
mouse IgM and absorbances analysed at 450 nm. Results are themean of triplicates± SD.
c Cell surface markers were examined in spleens of vaccinated, non-vaccinated or
control mice after incubation with different antibodies conjugated with ﬂuorochromes
and analyse by FACS. Results corresponded to the mean of the percentages of positive
cells ± SD.
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weaker MHC-II binding epitope containing two α-helices, elicited the
highest DC activation, the strongest DTH immune responses and the
highest production of IL-12. These properties conferred the greatest
protection in mouse strains at either high or low susceptibility to
listeriosis. The GAPDH1–15 epitope possessed these minimal require-
ments and proved to have similar protective efﬁcacy to the longer
GAPDH1–22 epitope. This methodology might help to design new
human and veterinary vaccines against listeriosis, an area of need
given the increasing incidence of this disease in European countries
(Peña-Sagredo et al., 2008; Valero and Rafart, 2014; Pérez-Trallero
et al., 2014). The methodology used in this study to predict the best T-
cell epitopes for vaccine design,might be useful in design of DC vaccines
against other infectious diseases, and notably the protective GAPDH1–15
epitope showed 98% homology with S. pneumonia and Streptococcus
pyogenes (Alvarez-Dominguez et al., 2008).Disclosures
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